BRIEF—AstraZeneca set for Japanese approval in lung cancer

AstraZeneca has reportedly been given a positive recommendation from the Japanese health ministry for its PD-L1 inhibitor Imfinzi (durvalumab).

The positive opinion relates to the firm’s application to market the drug as a treatment for stage III non-small cell lung cancer (NSCLC), and the Japanese medicines regulator is expected to deliver a final decision for this indication in June.

The drug was approved in this indication by the US regulator earlier this year.